Clinical Approach to Progressive Supranuclear Palsy.

Area of Science:

• Neurology
• Neuroscience
• Pathology

Background:

• Progressive supranuclear palsy (PSP) was identified 60 years ago.
• Diverse clinical phenotypes beyond Richardson's syndrome (RS) are now recognized in PSP.
• Clinical heterogeneity in PSP correlates with the regional distribution and severity of abnormal tau accumulation and neuronal loss.

Purpose of the Study:

• To explore the relationship between clinical phenotypes and underlying tau pathology in PSP.
• To evaluate the utility of clinical pointers for antemortem prediction of PSP subtypes.
• To review current diagnostic and treatment strategies for PSP.

Main Methods:

• Review of clinical and pathological data from PSP cases.
• Correlation of clinical features with neuroimaging findings (MRI).
• Assessment of emerging biomarkers, including cerebrospinal fluid (CSF) analysis and tau-PET imaging.

Main Results:

• Clinical heterogeneity in PSP is linked to the variability of tau pathology.
• Midbrain atrophy on MRI correlates with the RS phenotype but does not predict PSP pathology.
• CSF biomarkers and tau-PET imaging show promise for PSP diagnosis.

Conclusions:

• Clinical pointers can aid in the antemortem prediction of specific PSP-tau pathologies.
• A multidisciplinary approach is essential for managing the complex needs of PSP patients.
• Further research into biomarkers is crucial for improving PSP diagnosis and understanding.